@Article{Zhang2019, journal="Archives of Medical Science", issn="1734-1922", year="2019", title="Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors", abstract="Significant progresses have been made in adoptive cell therapy with CAR-T cells for cancers, especially for hematological malignancies. However, the treatment of solid tumors still poses a tremendous challenge and remains an unmet medical need. Several factors are held responsible for the inadequate responses: tumor heterogeneity, inefficient homing of T cells to tumor tissues, immunosuppressive microenvironment and the shortage of specific antigens shortage. Mesothelin is a cell-surface glycoprotein highly expressed in many types of solid tumors. As such, it has attracted much attention as a molecular target in cancer immunotherapy. Here, we delineate the barriers imposed by solid tumors on CARs, outline the rationale of mesothelin as a target for immunotherapy, summarize the preclinical and clinical results of mesothelin-targeted therapies, and extrapolate the expected results of CAR-T cells directed against mesothelin for solid tumors.", author="Zhang, Gui-Zhen and Li, Tian-Fang and Han, Shuang-Yin", doi="10.5114/aoms.2019.84888", url="http://dx.doi.org/10.5114/aoms.2019.84888" }